Clinical trials: Unresectable Malignant Neoplasm
Metastatic or Unresectable Cutaneous Melanoma
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC)…
- Trial name
- NCT01763164
- Testing
- MEK162, Dacarbazine
- Where
- 229 sites in United States, Argentina and 25 more
- Volunteers
- 402 people
- Sponsor
- Pfizer
Sarcoma
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
This is a Phase Ib/II experimental, open-label, dose escalation, active treatment study designed to determine the safety, tolerability, and recommended dose of the combination.
- Trial name
- GemTax (NCT01879085)
- Testing
- Docetaxel, Gemcitabine, Vorinostat
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Melissa Burgess, MD
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating children who have advanced…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00024258
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before.
- Trial name
- NCT03734029
- Testing
- Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin
- Where
- 208 sites in United States, Austria and 18 more
- Volunteers
- 557 people
- Sponsor
- Daiichi Sankyo
Metastatic or Unresectable Melanoma
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
The purpose of this study is to evaluate how effective the study drugs, nivolumab (also known as Opdivo®) and talazoparib (also known as Talzenna®) are when given as a combination treatment for unresectable or metastatic…
- Trial name
- NCT04187833
- Testing
- Nivolumab, Talazoparib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Melanoma
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
This study will examine the effectiveness and safety of glembatumumab vedotin as monotherapy or in combination with immunotherapies in patients with advanced melanoma.
- Trial name
- NCT02302339
- Testing
- glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
- Where
- 14 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
This randomized phase II trial studies how well liver surgery and chemotherapy compared to chemotherapy alone work in treating patients with colorectal cancer that has spread to the liver (liver metastases) that can be removed by…
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Recurrent Colorectal Carcinoma
- Trial name
- NCT02738606
- Testing
- Chemotherapy, Laboratory Biomarker Analysis, Metastasectomy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior…
- Trial name
- NCT01668784
- Testing
- Nivolumab, Everolimus
- Where
- 168 sites in United States, Argentina and 22 more
- Volunteers
- 821 people
- Sponsor
- Bristol-Myers Squibb
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer
- Trial name
- NCT00730483
- Testing
- PVA microporous hydrospheres/doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yale University
Unresectable Metastatic Colo-rectal Cancer
Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer
The primary objective of this study is to evaluate the safety and efficacy of Irinotecan Bead in combination with intravenous chemotherapy versus intravenous chemotherapy alone in the treatment of unresectable liver metastases in…
- Trial name
- PARAGON (NCT00816777)
- Testing
- Chemoembolization with irinotecan Bead, Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Generic Devices Consulting, Inc.
Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
This phase I/II trial studies the side effects and best dose of veliparib and topotecan hydrochloride and to see how well they work in treating patients with solid tumors, ovarian cancer that has come back or does not respond to…
- Conditions
- Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01012817
- Testing
- Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
- Where
- 15 sites in United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or…
- Trial name
- coBRIM (NCT01689519)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 495 people
- Sponsor
- Hoffmann-La Roche
Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
This phase I/II trial studies the best dose and side effects of navitoclax and how well it works when given together with vistusertib in treating patients with small cell lung cancer and solid tumors that have come back…
- Conditions
- Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
- Trial name
- NCT03366103
- Testing
- Navitoclax, Vistusertib
- Where
- 14 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
HER2 Positive Breast Cancer
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
This study is being done to see if tucatinib works better than placebo to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma.
- Trial name
- HER2CLIMB (NCT02614794)
- Testing
- tucatinib, capecitabine, trastuzumab
- Where
- 176 sites in United States, Australia and 13 more
- Volunteers
- 612 people
- Sponsor
- Seagen Inc.
Neuroendocrine Tumors, Carcinoid Tumors
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied.
- Trial name
- NCT01253161
- Testing
- Pasireotide Long Acting Release (LAR)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic or Unresectable Solid Tumor Malignancy
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
The investigators propose this Phase I trial of the combination of AUY922 and capecitabine to determine the maximum tolerated dose (MTD) in patients with advanced solid tumors.
- Trial name
- NCT01226732
- Testing
- Capecitabine, Hsp90 Inhibitor AUY 922
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- SCRI Development Innovations, LLC
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.
- Trial name
- NCT01661179
- Testing
- Vandetanib 300mg
- Where
- 4 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless…
- Trial name
- DPT01 (NCT04639219)
- Testing
- Trastuzumab deruxtecan
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
This is a Phase 1 open-label study to study the safety and activity of aldoxorubicin with ifosfamide/mesna in subjects with metastatic, advanced, unresectable soft tissue sarcoma.
- Trial name
- NCT02235701
- Testing
- 170 mg/m2 aldoxorubicin, 250 mg/m2 aldoxorubicin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- ImmunityBio, Inc.
Advanced Malignant Solid Neoplasm, Anal Carcinoma
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period…
- Conditions
- Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT02408861
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 34 sites in United States, Australia
- Volunteers
- 79 people
- Sponsor
- National Cancer Institute (NCI)